文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗晚期黑色素瘤患者的汇总长期结局

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2024-11-06

该汇总分析纳入六项CheckMate研究中未经免疫检查点抑制剂治疗的不可切除或转移性黑色素瘤患者,比较纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药的长期总生存。联合组中位随访45.0个月,单药组35.8个月,联合组总生存优于单药组(HR 0.78,95%CI 0.67至0.91),6年总生存率分别为52%与41%。

要点

  • 联合组6年总生存率为52%,单药组为41%,联合组总生存更长(HR 0.78)。
  • BRAF突变型与野生型患者及乳酸脱氢酶正常与升高患者中均观察到一致的获益。
  • 多变量分析与分类回归树分析中,乳酸脱氢酶高于正常上限与两种治疗下生存缩短相关。

核心结论

  • 在这项大型汇总非随机回顾性分析中,纳武利尤单抗联合伊匹木单抗较纳武利尤单抗单药在未经免疫检查点抑制剂治疗的晚期黑色素瘤患者中提供更长的总生存。
  • 分析识别出似乎与每种治疗生存相关的临床因素,可能有助于治疗决策。

研究设计与样本

  • 汇总六项CheckMate研究的数据,纳入未经免疫检查点抑制剂治疗、接受纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg或纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg,或纳武利尤单抗3 mg/kg单药治疗的患者。
  • 联合组839例,单药组536例;在各治疗组内进行Cox比例多变量分析和分类回归树分析。

主要发现

  • 联合组中位总生存随访45.0个月,单药组35.8个月。
  • 联合组总生存长于单药组(风险比0.78,95%CI 0.67至0.91),6年总生存率分别为52%与41%。
  • BRAF突变型和BRAF野生型患者以及乳酸脱氢酶正常和升高患者中均观察到一致的获益。
  • 按PD-L1表达水平也观察到总生存的数值差异,在无或低PD-L1表达时更为明显。
  • 多变量分析和分类回归树分析中,与两种治疗下生存缩短相关的临床因素为乳酸脱氢酶高于正常上限;联合组中年龄≥65岁、单药组中存在肝转移亦与生存缩短相关。

局限性

  • 原文自述为大型汇总非随机回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination or monotherapy pooled across all major company-sponsored trials, as well as clinical factors associated with survival, in patients with immune checkpoint inhibitor (ICI) treatment-naïve unresectable/metastatic melanoma. METHODS: Data were pooled from six CheckMate studies in ICI treatment-naïve patients receiving NIVO + IPI (NIVO 1 mg/kg + IPI 3 mg/kg or NIVO 3 mg/kg + IPI 1 mg/kg) or NIVO monotherapy (3 mg/kg). OS was assessed for each treatment, as well as in select subgroups. Cox proportional multivariate analysis (MVA) and classification and regression tree (CART) analyses were performed within treatment arms. RESULTS: Median follow-up for OS was 45.0 months for patients treated with NIVO + IPI (n = 839) and 35.8 months for patients treated with NIVO (n = 536). OS was longer with NIVO + IPI versus NIVO monotherapy (hazard ratio, 0.78 [95% CI, 0.67 to 0.91]), with 6-year OS rates of 52% versus 41%, respectively. Consistent benefit was observed in BRAF-mutant and BRAF-wild-type patients and those with normal and elevated lactate dehydrogenase (LDH). Numerical difference in OS was also observed across PD-L1 expression levels, although more pronounced with no/low PD-L1 expression. Clinical factors associated with decreased survival in both the MVA and CART analyses were LDH > upper limit of normal with either treatment, age ≥65 years with NIVO + IPI, and the presence of liver metastases with NIVO monotherapy. CONCLUSION: In this large, pooled nonrandomized retrospective analysis, we observed that NIVO + IPI provides longer OS than NIVO in patients with ICI treatment-naïve advanced melanoma and identifies clinical factors that appear to be associated with survival for each treatment, which may assist with treatment decision making.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Larkin J, Schadendorf D, et al. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. J Clin Oncol. 2024. PMID: 39504507. doi:10.1200/JCO.24.00400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。